(Q37029513)

English

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study

scientific article published on February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study (English)

1 reference

Europe PubMed Central

17 August 2017

0 references

0 references

0 references

cannabinoid receptor

0 references

0 references

Marilyn Huestis

11

object named as

Marilyn A Huestis

1 reference

Europe PubMed Central

17 August 2017

Robert R. Conley

3

object named as

Robert R Conley

1 reference

Europe PubMed Central

17 August 2017

author name string

Deanna L Kelly

1

1 reference

Europe PubMed Central

17 August 2017

David A Gorelick

2

1 reference

Europe PubMed Central

17 August 2017

Douglas L Boggs

4

1 reference

Europe PubMed Central

17 August 2017

Jared Linthicum

5

1 reference

Europe PubMed Central

17 August 2017

Fang Liu

6

1 reference

Europe PubMed Central

17 August 2017

Stephanie Feldman

7

1 reference

Europe PubMed Central

17 August 2017

M Patricia Ball

8

1 reference

Europe PubMed Central

17 August 2017

Heidi J Wehring

9

1 reference

Europe PubMed Central

17 August 2017

Robert P McMahon

10

1 reference

Europe PubMed Central

17 August 2017

Stephen J Heishman

12

1 reference

Europe PubMed Central

17 August 2017

Kimberly R Warren

13

1 reference

Europe PubMed Central

17 August 2017

Robert W Buchanan

14

1 reference

Europe PubMed Central

17 August 2017

language of work or name

0 references

publication date

1 February 2011

1 reference

Europe PubMed Central

17 August 2017

Journal of Clinical Psychopharmacology

1 reference

Europe PubMed Central

17 August 2017

31

1 reference

Europe PubMed Central

17 August 2017

1

1 reference

Europe PubMed Central

17 August 2017

86-91

1 reference

Europe PubMed Central

17 August 2017

The endocannabinoid system and psychiatric disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Role of cannabis and endocannabinoids in the genesis of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The psychiatric side-effects of rimonabant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The endocannabinoid system: a new pharmacological target for obesity treatment?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The role of the endocannabinoid system in lipogenesis and fatty acid metabolism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The endocannabinoid system in obesity and type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Clinical practice. Nonsurgical management of obesity in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Role of the endocannabinoid system in energy balance regulation and obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Medical comorbidity in women and men with schizophrenia: a population-based controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Schizophrenia and increased risks of cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

The role of dopamine in reward and pleasure behaviour--review of data from preclinical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Diabetes mellitus and schizophrenia: historical perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Prevalence and Trends in Obesity Among US Adults, 1999-2000

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

Mortality in a cohort of patients with schizophrenia: a record linkage study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

29 September 2017

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

27 June 2018

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Assessment of capacity to give consent to research participation: state-of-the-art and beyond.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3717343

4 September 2018

Changes in body mass index for individuals with and without schizophrenia, 1987–1996

1 reference

https://pubmed.ncbi.nlm.nih.gov/21192149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic validity of assessment scales for depression in patients with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21192149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing depression in schizophrenia: the Calgary Depression Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/21192149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/JCP.0B013E318204825B

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37029513&oldid=1672035996"